Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Modeling serological testing to inform relaxation of social distancing for COVID-19 control

Alicia N.M. Kraay, Kristin N. Nelson, Conan Y. Zhao, David Demory, View ORCID ProfileJoshua S. Weitz, Benjamin A. Lopman
doi: https://doi.org/10.1101/2020.04.24.20078576
Alicia N.M. Kraay
1Rollins School of Public Health, Emory University, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: amullis@emory.edu
Kristin N. Nelson
1Rollins School of Public Health, Emory University, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Conan Y. Zhao
2School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA
3Interdisciplinary Graduate Program in Quantitative Biosciences, Georgia Institute of Technology, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Demory
2School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua S. Weitz
2School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA
4School of Physics, Georgia Institute of Technology, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joshua S. Weitz
Benjamin A. Lopman
1Rollins School of Public Health, Emory University, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Serological testing remains a passive component of the current public health response to the COVID-19 pandemic. Using a transmission model, we examined how serology can be implemented to allow seropositive individuals to increase levels of social interaction while offsetting transmission risks. We simulated the use of widespread serological testing in three metropolitan areas with different initial outbreak timing and severity characteristics: New York City, South Florida, and Washington Puget Sound. In our model, we use realistic serological assay characteristics, in which tested seropositive individuals partially restore their social contacts and act as immunological ‘shields’. Compared to a scenario with no intervention, beginning a mass serological testing program on November 1, 2020 was predicted to avert 15,000 deaths (28% reduction, 95% CrI: 0.4%-30.2%) in New York City, 3,000 (31.1% reduction, 95% CrI: 26.4%-33.3%) in South Florida and 10,000 (60.3% reduction, 95% CrI: 50.2%-60.7%) in Washington State by June 2021. In all three sites, widespread serological testing substantially blunted new waves of transmission. Serological testing has the potential to mitigate the impacts of the COVID-19 pandemic while also allowing a substantial number of individuals to safely return to social interactions and economic activity.

Significance The SARS-CoV-2 pandemic led many countries to implement broadly impactful social distancing interventions. In the U.S., many measures are still partially in place. While these policies slowed the epidemic, they also caused substantial social and economic disruption. Here, we explore how using available serological assays to inform the individualized relaxation of social distancing could allow a gradual return to more normal levels of economic and social activity while mitigating public health risk. We find that large scale serological testing in major metropolitan areas has the potential to lower expected COVID-19 deaths, reduce peak health system burden to manageable levels, and also allow social distancing interventions to be substantially relaxed.

Competing Interest Statement

BAL reports grants and personal fees from Takeda Pharmaceuticals and personal fees from World Health Organization outside the submitted work.

Funding Statement

BAL and ANMK were supported by the Vaccine Impact Modelling Consortium; BAL and KNN were supported by NIH/NICHD R01 HD097175; BAL, KNN, and ANMK were supported by NIH/NIGMS R01 GM124280; JSW and DD were supported by Simons Foundation (Scope Award ID 329108); BAL was supported by NSF 2032084; JSW was supported by the Army Research Office (W911NF1910384); JSW and CYZ was supported by National Science Foundation (1806606, 1829636, and 2032082).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was exempt from IRB review because all data were publicly available

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • This manuscript was revised to be fit to death and seroprevalence data from three metropolitan locations. Additionally, simulations using serological testing now start on November 1, 2020 given that a large scale testing strategy has yet to be rolled out. Additionally, David Demory was added as a coauthor.

Data Availability

Transmission model code and incidence data used are available at the links provided

https://coronavirus.jhu.edu/map.html

https://github.com/lopmanlab/Serological_Shielding

https://usafacts.org/visualizations/coronavirus-covid-19-spread-map/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 17, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Modeling serological testing to inform relaxation of social distancing for COVID-19 control
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Modeling serological testing to inform relaxation of social distancing for COVID-19 control
Alicia N.M. Kraay, Kristin N. Nelson, Conan Y. Zhao, David Demory, Joshua S. Weitz, Benjamin A. Lopman
medRxiv 2020.04.24.20078576; doi: https://doi.org/10.1101/2020.04.24.20078576
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Modeling serological testing to inform relaxation of social distancing for COVID-19 control
Alicia N.M. Kraay, Kristin N. Nelson, Conan Y. Zhao, David Demory, Joshua S. Weitz, Benjamin A. Lopman
medRxiv 2020.04.24.20078576; doi: https://doi.org/10.1101/2020.04.24.20078576

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (214)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1091)
  • Dentistry and Oral Medicine (194)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (497)
  • Epidemiology (9747)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2299)
  • Geriatric Medicine (221)
  • Health Economics (461)
  • Health Informatics (1548)
  • Health Policy (729)
  • Health Systems and Quality Improvement (600)
  • Hematology (236)
  • HIV/AIDS (500)
  • Infectious Diseases (except HIV/AIDS) (11623)
  • Intensive Care and Critical Care Medicine (615)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2136)
  • Nursing (133)
  • Nutrition (332)
  • Obstetrics and Gynecology (424)
  • Occupational and Environmental Health (516)
  • Oncology (1171)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (308)
  • Pediatrics (693)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2168)
  • Public and Global Health (4640)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (451)
  • Respiratory Medicine (622)
  • Rheumatology (273)
  • Sexual and Reproductive Health (224)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (42)
  • Transplantation (120)
  • Urology (94)